What are the main recommendations for clinical trial design during the COVID-19 pandemic?
Hundreds of registered clinical trials regarding potential therapies for COVID-19 are currently open in international registries. The study designs and outcomes are often divergent and based on a single center’s experience or compassionate use of the candidate treatments. To improve the quality of the evidence and secondary analysis, the scientific community should lead multi-center, multi-arm and highly powered clinical trials and foster the global sharing of knowledge on the COVID-19. This approach would empower the generation of high-quality data on efficacy and safety of potential therapies for COVID-19.180